Asterias Biotherapeutics, Inc., a development-stage biotechnology company, focuses on the development of therapeutic products to treat neurology, oncology, cardiology, metabolic diseases, ophthalmology, orthopedics, and blood and vascular diseases. It is also developing human embryonic stem cell programs, including cell lines and a Phase I clinical trial in patients with acute spinal cord injury; intellectual property related to its autologous cellular immunotherapy program, including a Phase I/II clinical trial of autologous immunotherapy in patients with acute myelogenous leukemia; and non-therapeutic applications of pluripotent stem cells, such as cellular assay products for use in drug development and toxicity screening. 
TypePublic
HQFremont, US
Founded2012
Size (employees)55 (est)+35%
Websiteasteriasbiotherapeutics.com
Asterias Biotherapeutics was founded in 2012 and is headquartered in Fremont, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Asterias Biotherapeutics

Ryan Chavez

Ryan Chavez

CFO
Craig Halberstadt

Craig Halberstadt

Ph.D. Senior Vice President, Research & Product Development
Show more

Asterias Biotherapeutics Office Locations

Asterias Biotherapeutics has an office in Fremont
Fremont, US (HQ)
6300 Dumbarton Cir
Show all (1)
Report incorrect company information

Asterias Biotherapeutics Financials and Metrics

Asterias Biotherapeutics Revenue

Asterias Biotherapeutics's revenue was reported to be $4.04 m in FY, 2017
USD

Revenue (Q3, 2018)

116.0k

Gross profit (Q3, 2018)

59.0k

Gross profit margin (Q3, 2018), %

50.9%

Net income (Q3, 2018)

(4.5m)

EBIT (Q3, 2018)

(5.4m)

Market capitalization (16-Jan-2019)

41.7m

Closing stock price (16-Jan-2019)

0.8

Cash (30-Sep-2018)

6.4m
Asterias Biotherapeutics's current market capitalization is $41.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3.6m7.0m4.0m

Revenue growth, %

94%

Cost of goods sold

268.0k128.0k165.0k

Gross profit

3.3m6.8m3.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

772.0k1.4m1.6m1.5m2.1m2.0m1.7m478.0k587.0k116.0k

Cost of goods sold

41.3k38.0k176.0k53.0k6.0k59.0k53.0k81.0k63.0k120.0k57.0k

Gross profit

734.0k1.2m1.5m1.5m2.0m2.0m1.6m415.0k467.0k59.0k

Gross profit Margin, %

95%88%97%100%97%97%95%87%80%51%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2.2m3.1m11.2m19.8m13.3m

Inventories

340.1k438.3k1.0m

Current Assets

50.1m18.4m29.8m37.0m22.7m

PP&E

5.8m5.5m4.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

91.6k325.8k12.9m15.6m7.6m21.5m17.9m8.6m10.5m9.2m6.4m

Accounts Receivable

2.4m

Inventories

1.2m

Current Assets

315.8k42.3m32.9m33.0m20.7m33.8m35.9m21.9m19.9m15.9m15.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(22.4m)(758.9k)(15.0m)(35.5m)(28.4m)

Depreciation and Amortization

220.6k564.0k3.9m3.8m

Inventories

(2.3k)(2.3k)(680.0k)

Accounts Payable

567.1k(24.0k)329.0k(675.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(4.8m)(2.3m)(5.1m)(3.6m)(3.5m)(10.3m)(5.2m)(10.6m)(6.3m)

Depreciation and Amortization

95.2k130.6k269.1k

Accounts Payable

353.7k(80.9k)(313.1k)1.4m399.0k1.9m251.0k640.0k737.0k

Cash From Operating Activities

(3.9m)(1.4m)(1.9m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Asterias Biotherapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Asterias Biotherapeutics News and Updates

Asterias Biotherapeutics Reports Third Quarter Results

Clinical Programs Continue to Progress Recent Transactions with affiliate of Novo Nordisk Increased Cash-on-Hand and Reduced Annual Operating Expenses Recently Announced Definitive Merger Agreement with BioTime Creates Leading Cell Therapy Company

Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018

FREMONT, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announc…

Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study

Meeting with Food and Drug Administration Remains on Track for End of 2018

Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018

FREMONT, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announce…
Show more
Report incorrect company information

Asterias Biotherapeutics Company Life and Culture

Report incorrect company information

Asterias Biotherapeutics Frequently Asked Questions

  • When was Asterias Biotherapeutics founded?

    Asterias Biotherapeutics was founded in 2012.

  • Who are Asterias Biotherapeutics key executives?

    Asterias Biotherapeutics's key executives are Ryan Chavez and Craig Halberstadt.

  • How many employees does Asterias Biotherapeutics have?

    Asterias Biotherapeutics has 55 employees.

  • What is Asterias Biotherapeutics revenue?

    Latest Asterias Biotherapeutics annual revenue is $4 m.

  • What is Asterias Biotherapeutics revenue per employee?

    Latest Asterias Biotherapeutics revenue per employee is $73.5 k.

  • Who are Asterias Biotherapeutics competitors?

    Competitors of Asterias Biotherapeutics include Cannabis Sativa, CTD Holdings and Enanta Pharmaceuticals.

  • Where is Asterias Biotherapeutics headquarters?

    Asterias Biotherapeutics headquarters is located at 6300 Dumbarton Cir, Fremont.

  • Where are Asterias Biotherapeutics offices?

    Asterias Biotherapeutics has an office in Fremont.

  • How many offices does Asterias Biotherapeutics have?

    Asterias Biotherapeutics has 1 office.